布地奈德联合特异性免疫治疗对支气管哮喘患儿1，25-二羟维生素D3及IL-6、IL-10水平的影响

目的探究布地奈德联合特异性免疫治疗对支气管哮喘患儿1，25-二羟维生素D3及白介素6(interleukin-6, IL-6)、白介素10(interleukin-10, IL-10)水平的影响。 方法选取我院2017年6月至2019年6月73例支气管哮喘患儿作为研究对象，分为观察组38例和对照组35例。对照组给予布地奈德治疗，观察组则再联合舌下含服粉尘螨滴剂行特异性免疫治疗。比较治疗前后两组患儿哮喘症状评分、肺功能和血清1，25-二羟维生素D3及IL-6、IL-10水平。 结果治疗1年、2年后，两组患者哮喘症状及ACT评分均有下降，且观察组患者哮喘症状及ACT评分分别为(0.95±0.46、0.46±0.38)分和(1.14±0.51、0.74±0.42)分，差异均有统计学意义(P<0.05)。观察组患者肺功能观察组患者第1 s用力呼气量(forced expiratory volume in 1 s, FEV₁)、用力肺活量(forced vital capacity, FVC)、FEV₁%预计值、FVC%预计值及FEV₁/FVC和对照组比较均明显上升(P<0.05)。治疗后，两组患儿血清IgE、IL-6水平下降，1，25-二羟维生素D3和IL-10水平明显升高，且观察组上述指标均明显优于对照组(P<0.05)。 结论特异性免疫疗法联合布地奈德治疗儿童支气管哮喘可有效增加患儿血清1，25-二羟维生素D3和IL-10水平，减少IgE及IL-6，改善机体组织过敏原的免疫耐受能力，同时还能显著改善哮喘症状及肺功能，具有良好的临床疗效。

Effects of budesonide combined with specific immunotherapy on the levels of 1,25-dihydroxyvitamin D3,IL-6 and IL-10 in children with bronchial asthma

Objective To investigate the effect of budesonide combined with specific immunotherapy on the levels of 1,25-dihydroxyvitamin D3,IL-6 and IL-10 in children with bronchial asthma.Methods 73 children with bronchial asthma in our hospital from June 2017 to June 2019 were selected as the study objects,and randomly divided into observation group 38 cases and control group 35 cases.The control group was treated with budesonide.While,the observation group was received specific immunotherapy in combination with sublingual dust mite drops.Asthma symptom scores,lung function and serum levels of 1,25-dihydroxyvitamin D3,IL-6 and IL-10 were compared between the two groups before and after treatment.Results After 1 year and 2 years of treatment,the asthma symptoms and ACT scores of the two groups were decreased,and the asthma symptoms and ACT scores of the observation group were(0.95±0.46,0.46±0.38)and(1.14±0.51,0.74±0.42),respectively.The differences were statistically significant(P<0.05).FEV 1,FVC,FEV 1%predicted value,FVC%predicted value and FEV 1/FVC were all significantly increased in the observation group compared with the control group(P<0.05).After treatment,the serum IgE and IL-6 levels of the two groups were decreased,and the levels of 1,25-dihydroxyvitamin D3 and IL-10 were increased significantly.And the above indicators in the observation group were significantly better than those in the control group(P<0.05).Conclusion The treatment of specific immunotherapy combined with budesonide for bronchial asthma in children could effectively increase serum levels of 1,25-dihydroxyvitamin D3 and IL-10,reduce IgE and IL-6,which improve immune tolerance to allergens in body tissues,and significantly promote asthma symptoms and lung function with good clinical efficacy.